Share Twitter LinkedIn Facebook Email Sara Tolaney, MD from Dana Farber Cancer Institute speaks about the SABCS 2021 Presentation – Heterogeneity in treatment outcomes for HER2+ breast cancer – clinical management strategies.
Enhertu DESTINY-Breast06 Phase III Study the Impact on HR-Positive, HER2-Low Metastatic Breast Cancer Revealed Breast 4 Mins Read
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read